Surfing the NASH Tsunami

By HEP Dynamics LLC

Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Stephen Harrison, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green as they discuss the issues affecting the evolving NASH market from their own unique perspectives on the Surfing the NASH Tsunami podcast. #NASH #NAFLD #FattyLiver

  1. 1.
    S2-E50.3 - "Dare to Dream" - How New Imaging Methods Can Change Our Future
    13:59
  2. 2.
    S2-E50.2 - "Seeing What Should Be" - Imaging the Liver To Assess Functioning Hepatocytes
    11:28
  3. 3.
    S2-E50.1 - "Potential Game Changer" - Imaging Can Provide a Dynamic View of NASH Evolution
    14:55
  4. 4.
    S2-E50 - "Dare to Dream" - the Exciting, Evolving World of Organ Imaging
    50:47
  5. 5.
    S2-E49.3 - Clinical Care Pathway: What Can Be Done Today?
    18:02
  6. 6.
    S2-E49.2 - Clinical Care Pathway: Behavior Change and Prevalence Data
    12:50
  7. 7.
    S2-E49.1 - Clinical Care Pathway: How It Came To Be
    15:45
  8. 8.
    S2-E49 - Finally, a Clinical Care Pathway For a Hidden Pandemic!
    51:09
  1. 9.
    S2-E48.4 - Closing Thoughts On Summer: What Mattered Most?
    11:18
  2. 10.
    S2-E48.3 - Closing thoughts on Summer: Looking From a Patient-Based Perspective
    13:45
  3. 11.
    S2-E48.2 - Closing Thoughts On Summer: More on FGF-21s and A Topical "Hijacking"
    12:25
  4. 12.
    S2-E48.1 - Closing Thoughts On Summer: Mazen Noureddin's Two Big Things
    11:44
  5. 13.
    S2-E48 - Closing Thoughts On an Eventful NASH Summer
    50:47
  6. 14.
    S2-E47.3 - Most Important Story of Summer? Manal Abdelmalek Says, "NIH Funding Liver Cirrhosis Network"
    27:20
  7. 15.
    S2-E47.2 - Most Important Story of Summer? Michelle Long Says, "Harrison/Alkhouri Prevalence Paper."
    22:17
  8. 16.
    S2-E47.1 - Most important Story of Summer? Ian Rowe says, "FDA ELF Approval."
    22:29
  9. 17.
    S2-E47 - Ask Opinion Leaders: The Biggest NAFLD/NASH Stories of Summer
    1:13:17
  10. 18.
    S2-E46.3 - Top Stories From Paris NASH: Connecting the Dots
    14:26
  11. 19.
    S2-E46.1 - Top stories from Paris NASH: Epidemiology and Clinical Aspects
    13:07
  12. 20.
    S2-E46.2 - Top Stories From Paris NASH: Deep Dive into Fibrosis
    12:27
  13. 21.
    S2-E46 - Highlights from Paris NASH
    48:54
  14. 22.
    S2-E45.3 - Discussing the EASL Guidelines and the Path to A Non-Invasive Testing Future with Donna Cryer
    25:35
  15. 23.
    S2-E45.2 - Discussing Non-Invasive Testing and the Patient Experience with Wayne Eskridge.
    26:18
  16. 24.
    S2-E45.1 - Discussing Fatty Liver Disease Prevalence And Patient Awareness With Anthony Villiotti
    29:02
  17. 25.
    S2-E45 - Ask the Advocates: The Biggest NAFLD/NASH Story of the Summer
    1:10:41
  18. 26.
    S2-E44.4 - COVID-19 and Fatty Liver - What Impact Will the Delta Variant Have On Clinical Trials?
    11:53
  19. 27.
    S2-E44.3 - COVID-19 And Fatty Liver - Areas for Confusion and Policy Discord
    13:58
  20. 28.
    S2-E44.2 - COVID-19 And Fatty Liver - Lessons from Immunocompromised Patients and Other Countries
    13:42
  21. 29.
    S2-E44.1 - COVID-19 And Fatty Liver --How Immunocompromised and Transplant Patients Became A Priority for Booster Doses
    14:40
  22. 30.
    S2-E44 - The impact Of the COVID-19 Delta Variant on NAFLD and NASH
    1:02:59
  23. 31.
    S2-E43.4 -Rethinking Cirrhosis: A Call To Action
    11:12
  24. 32.
    S2-E43.3 - Driving A Reconsideration Of Cirrhosis In Drug Development
    12:08
  25. 33.
    S2-E43.2 - Rethinking Cirrhosis As A Target For Drug Development
    11:50
  26. 34.
    S2-E43.1 - Cirrhosis - Challenges in Treating Patients
    11:46
  27. 35.
    S2-E43 - Can Cirrhosis Drive Drug Development In NASH?
    53:10
  28. 36.
    S2-E42.3 - Why FGFs Matter - Episode Opening and Closing, Plus a Question About Screen Fail Rates
    12:34
  29. 37.
    S2-E42.2 - How FGFs Work In The Body And What This Means For NAFLD And NASH
    12:04
  30. 38.
    S2-E42.1 - FGF drugs in Development - A Promising Class of Agents
    15:31
  31. 39.
    S2-E42 - How Do Fibroblast Growth Factor (FGF) Drugs Work and Why Are They So Important?
    50:08
  32. 40.
    S2-E41.4 - Reasons To Believe That a Multidisciplinary Fight Against NASH Will Bring Value
    20:29
  33. 41.
    S2-E41.3 - Critical Success Factors In the Multidisciplinary Fight Against NASH
    12:24
  34. 42.
    S2-E41.2 - Specialties and Organizations Unite to Fight the NASH Epidemic
    12:48
  35. 43.
    S2-E41.1 - SPECIAL FEATURE: Interview with Louise Campbell
    23:32
  36. 44.
    S2-E41 - Preparing for the NASH Epidemic: Behind a Multidisciplinary Call to Action
    51:49
  37. 45.
    S2-E40.3 - Discussing Comprehensive Care Models For NAFLD - Metrics, Key Performance Indicators and Improving Management
    14:58
  38. 46.
    S2-E40.2 - Discussing Comprehensive Care Models For NAFLD - Providers Respond
    16:27
  39. 47.
    S2-E40.1 - Discussing Comprehensive Care Models for NAFLD - Jeff Lazarus Presents Research
    13:47
  40. 48.
    S2-E40 - Discussing Comprehensive Care Models for NAFLD
    1:02:50
  41. 49.
    S2-E39.3 - 20K Celebration Interview With Jörn Schattenberg and Ian Rowe
    42:39
  42. 50.
    S2-E39.2 - 20K Celebration Interviews With Stephen Harrison and Naim Alkhouri
    44:37

Listen to Surfing the NASH Tsunami now.

Listen to Surfing the NASH Tsunami in full in the Spotify app